Which Molecular Tests to Order for Colorectal Cancer

November 19, 2019
7:30-8 am CST

Cost

Free for all participants.

Overview

By the end of this presentation, the audience will be able to describe the utility of microsatellite instability testing in colorectal cancer care and discuss the limitations of various assays used to diagnose microsatellite instability. The audience will also be able to describe the relevance of KRAS, NRAS, HRAS, and BRAF mutations in colorectal cancer care along with an approach to testing that ensures appropriate test utilization. Molecular alterations that predict responsiveness to currently available targeted therapies will also be discussed.

Presenter

Rondell Graham, M.B.B.S.
Associate Professor of Laboratory Medicine and Pathology
Division of Anatomic Pathology
Mayo Clinic, Rochester, Minnesota

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the clinical utility of microsatellite instability testing in colorectal cancer care.
  • Discuss the significance of KRAS, NRAS, HRAS, and BRAF mutations in colorectal cancer.
  • List alterations that predict responsiveness to currently available targeted therapies.

Intended Audience

This webinar is designed for Oncologists, Pathologists, and Laboratory Directors.

Credit

The following types of credit are offered for this event:
ASCLS P.A.C.E.®

Level of instruction for this program is intermediate.

To obtain credit:

  1. Register for and participate in the program.
  2. Complete the evaluation that will be sent to you after the program.
  3. Generate and print your certificate(s).

ASCLS P.A.C.E.®

Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.® program. This program has been approved for a maximum of 0.5 P.A.C.E.® contact hour.

Faculty Disclosure

Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.

Questions?

Contact us: mcleducation@mayo.edu

Additional Resources

RAS/RAF Targeted Gene Panel [A Test in Focus]
MCL Education

MCL Education

This post was developed by our Education and Technical Publications Team.